HOME › Research Insight › Injectable Drug Delivery Market - Global Forecasts to 2017
Injectable Drug Delivery Market - Global Forecasts to 2017
Injectable drug delivery devices market ranges from traditional conventional syringes to advanced auto injectors. The market is highly competitive and the key companies have created a space for themselves in different technological areas. The conventional and self injection devices market is dominated by three to four major players, who together take up more than 85% of the market.
Becton Dickinson & Co. (U.S.) hasemerged as the market leader in the conventional injection devices market.The company offers a wide product portfolio which includes both conventional and self injectable devices. BD ensures continuous supply of products with exception of certain medical devices and seasonal products. It has wide range of customers for its injectable products including hospitals and clinics, physicians office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers. The company has adopted strategies such as acquisition, product enhancement, geographical expansion, and new product launch to maintain its leadership position in the conventional devices market. Innovative products provide a competitive edge to the company. The company launched worlds first Safety-Engineered Pen Needle, worlds smallest pen needle BD Ultra-Fine Nano and advanced needle technology called PentaPoint during 2012 and 2011.
Baxter International, Inc. (U.S.) possesses the capability to provide a stiff competition to Becton Dickinson & Co. (U.S.). Baxter has its own direct sales force which use different methods for sales and distribution such as frequent contact by sales representatives, automated communications via various electronic purchasing systems, direct-mail campaigns among others. To support international sales the company has a strong distribution network of sales agents in more than 100 countries. The company focuseson broadening its product portfolio by acquiring allied injectable companies. During 2012 to 2010 it undertook 3 acquisitions: Baxa Corporation (U.S.), Prism Pharmaceuticals, Inc. (U.S.), and ESI Lederle (ESI).
Improving patient compliance for self injectable devices has triggered the influx of prominent device manufacturers across the globe. The market for self injectable devices is slightly fragmented, with different companies excelling in different self injection technologies (Pen injectors, Auto injectors, Needle free injectors). The key players operating in the market include SHL Group (Taiwan), Ypsomed Holding AG (Switzerland), and Owen Mumford, Ltd. (U.K.). Amongst these key players, SHL Group (Taiwan) has emerged as the market leader in the self injection devices market.The company has a broad product portfolio in the self-injection devices market and has undertaken several expansions to further increase its manufacturing capabilities. Between 2013 and 2010, SHL expanded its auto injector facility in Taiwan, completed the expansion of auto injector facility in Northern Taiwan, improved assemble line production process of auto injectors by applying various in house automation solutions, and established a new manufacturing facility- SHL Pharma Systems in South Florida, U.S. Ypsomed Holding AG (Switzerland), due to its extensive patent portfolio and comprehensive range of products in injection systems, closely competes with SHL Group (Taiwan) in the self injectable devices market. Ypsomeds concentrated focus on R&D ensures incessant new product launches and a number of injection system projects in the pipeline. During 2012 to 2010, the company launched four new injectable products.
Some of the prominent strategic moves undertaken by leading players in injectable drug delivery market include expansion, agreements, partnerships, and collaborations. Players adopt expansion as a strategy to increase their production capacity and customer base, which ultimately results in increased sales and provides competitive advantage. For instance, Gerresheimer AG (Germany) completed as much as nine expansions during 2011 to 2013 that increased its production capacity of injection systems. Like expansion strategy, agreements, partnerships, and collaborations strategies also augment the capabilities of a company. Prominent firms like Ypsomed Holdings AG and Antares Pharma, Inc. have been actively entering into several agreements to accelerate their market growth.
Injectable drug delivery technologies market is technology driven and innovations provide an impetus to the market. This is evident from several FDA approvals and launch of new products. During 2010 to 2012, the industry witnessed about 13 new approved products and 24 different product launches by players in the market. Advancements in technology help a patient in ease of administration, fast action, and reduced pain. The device manufacturers have been alert enough to address the minute needs of patients, which is evident from the entry of several innovative technologies in the market. One of the noteworthy innovations is the FDA approved Auvi-Q; it is a talking injection device by Sanofi-Aventis which is used for treatment of life-threatening allergic reactions. Demand for innovation encourages companies to invest in injectable drug delivery technologies.
Related Reports @
Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017
North - Dominion Plaza,
Suite 800, Dallas, TX 75252